Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Steven Douglas Maynard & Jeff Gelblum. (2013) Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease. Neuropsychiatric Disease and Treatment 9, pages 1619-1627.
Read now
Read now
Serge Gauthier, Alain Robillard, Sharon Cohen, Sandra Black, John Sampalis, Diane Colizza, Frederica de Takacsy & Robyn Schecter. (2013) Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Current Medical Research and Opinion 29:8, pages 989-1000.
Read now
Read now
Piera Sozio, Laura S Cerasa, Lisa Marinelli & Antonio Di Stefano. (2012) Transdermal donepezil on the treatment of Alzheimer’s disease. Neuropsychiatric Disease and Treatment 8, pages 361-368.
Read now
Read now
Paul T Francis, Chris G Parsons & Roy W Jones. (2012) Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease. Expert Review of Neurotherapeutics 12:11, pages 1351-1365.
Read now
Read now
Tim Karl, David Cheng, Brett Garner & Jonathon C. Arnold. (2012) The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opinion on Therapeutic Targets 16:4, pages 407-420.
Read now
Read now
Cesare Mancuso, Raffaella Siciliano, Eugenio Barone, David Allan Butterfield & Paolo Preziosi. (2011) Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opinion on Investigational Drugs 20:9, pages 1243-1261.
Read now
Read now
Seong Hye Choi, Kyung Won Park, Duk L. Na, Hyun Jeong Han, Eun-Joo Kim, Yong S. Shim, Jae-Hong Lee & The EXPECT Study Group. (2011) Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Current Medical Research and Opinion 27:7, pages 1375-1383.
Read now
Read now
Tomasz Sobow. (2010) Combination treatments in Alzheimer’s disease: risks and benefits. Expert Review of Neurotherapeutics 10:5, pages 693-702.
Read now
Read now
Articles from other publishers (31)
Hui Yue, Hong-rui Bao, Yan-yin Cui, Wen-xin Hou & Hong-juan Wen. 2024. Computational and Experimental Simulations in Engineering. Computational and Experimental Simulations in Engineering
1211
1222
.
Oliver Riedel, Malte Braitmaier & Ingo Langner. (2022) Dementia in health claims data: The influence of different case definitions on incidence and prevalence estimates. International Journal of Methods in Psychiatric Research 32:2.
Crossref
Crossref
Ekta Shirbhate, Vijay K. Patel, Priya Tiwari, Rakesh Kore, Ravichandran Veerasamy, Achal Mishra & Harish Rajak. (2022) Combination Therapy for the Treatment of Alzheimer’s Disease: Recent
Progress and Future Prospects. Current Topics in Medicinal Chemistry 22:22, pages 1849-1867.
Crossref
Crossref
Bandna Gupta & Kopal Rohatgi. 2022. Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition). Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition)
218
260
.
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
231
269
.
João Pinho, Miguel Quintas-Neves, Imis Dogan, Kathrin Reetz, Arno Reich & Ana Sofia Costa. (2021) Incident stroke in patients with Alzheimer’s disease: systematic review and meta-analysis. Scientific Reports 11:1.
Crossref
Crossref
Md. Farhad Hossain, Ni Wang, Ruijun Chen, Siwen Li, Jaydeep Roy, Md. Giash Uddin, Zhong Li, Lee Wei Lim & You-Qiang Song. (2021) Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer’s disease neuropathology. Ageing Research Reviews 67, pages 101304.
Crossref
Crossref
Kevin Nguyen, Heidi Hoffman, Binu Chakkamparambil & George T Grossberg. (2021) Evaluation of rivastigmine in Alzheimer's disease. Neurodegenerative Disease Management 11:1, pages 35-48.
Crossref
Crossref
Naseem Akhtar, Varsha Singh, Mohammad YusufRiaz A. Khan. (2020) Non-invasive drug delivery technology: development and current status of transdermal drug delivery devices, techniques and biomedical applications. Biomedical Engineering / Biomedizinische Technik 65:3, pages 243-272.
Crossref
Crossref
Md. Tanvir Kabir, Md. Sahab Uddin, Abdullah Al Mamun, Philippe Jeandet, Lotfi Aleya, Rasha A. Mansouri, Ghulam Md Ashraf, Bijo Mathew, May N. Bin-Jumah & Mohamed M. Abdel-Daim. (2020) Combination Drug Therapy for the Management of Alzheimer’s Disease. International Journal of Molecular Sciences 21:9, pages 3272.
Crossref
Crossref
Steve Pedrini, Mike Morici & Ralph N. Martins. 2019. Neurodegeneration and Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease
391
442
.
M.A. Arya, Maneesha K. Manoj Kumar, M. Sabitha, Krishnakumar N. Menon & Sreeja C. Nair. (2019) Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer's disease. Journal of Drug Delivery Science and Technology 51, pages 297-309.
Crossref
Crossref
Aura M. Hurtado-Puerto, Cristina Russo & Felipe Fregni. 2018. Clinical Trials in Neurology. Clinical Trials in Neurology
297
338
.
Alireza Basiri, Basma M. Abd Razik, Mohammed Oday Ezzat, Yalda Kia, Raju Suresh Kumar, Abdulrahman I. Almansour, Natarajan Arumugam & Vikneswaran Murugaiyah. (2017) Synthesis and cholinesterase inhibitory activity study of new piperidone grafted spiropyrrolidines. Bioorganic Chemistry 75, pages 210-216.
Crossref
Crossref
Soo J Yoon, Seong H Choi, Hae R Na, Kyung-Won Park, Eun-Joo Kim, Hyun J Han, Jae-Hong Lee, Young S Shim & Duk L Na. (2017) Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine. Geriatrics & Gerontology International 17:3, pages 494-499.
Crossref
Crossref
Kelvin K.F. Tsoi, Joyce Y.C. Chan, Michael P.F. Wong & Timothy C.Y. Kwok. (2016) Response to the Letter to the Editor by Shinji Matsunaga “Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials”. Journal of the American Medical Directors Association 17:11, pages 1063.
Crossref
Crossref
Shinji Matsunaga, Taro Kishi & Nakao Iwata. (2016) Tsoi KK et al: Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials. Journal of the American Medical Directors Association 17:11, pages 1061-1062.
Crossref
Crossref
Kelvin K.F. Tsoi, Joyce Y.C. Chan, Nelson W.Y. Leung, Hoyee W. Hirai, Samuel Y.S. Wong & Timothy C.Y. Kwok. (2016) Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials. Journal of the American Medical Directors Association 17:9, pages 863.e1-863.e8.
Crossref
Crossref
Radoslaw Magierski & Tomasz Sobow. (2015) Benefits and risks of add-on therapies for Alzheimer's disease. Neurodegenerative Disease Management 5:5, pages 445-462.
Crossref
Crossref
David Cheng, Jac Kee Low, Warren Logge, Brett Garner & Tim Karl. (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice. Psychopharmacology 231:15, pages 3009-3017.
Crossref
Crossref
Serge Gauthier & José L. Molinuevo. (2012) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease. Alzheimer's & Dementia 9:3, pages 326-331.
Crossref
Crossref
Muriel Noetzli & Chin B. Eap. (2013) Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease. Clinical Pharmacokinetics 52:4, pages 225-241.
Crossref
Crossref
Konstantina G. Yiannopoulou & Sokratis G. Papageorgiou. (2012) Current and future treatments for Alzheimer’s disease. Therapeutic Advances in Neurological Disorders 6:1, pages 19-33.
Crossref
Crossref
Martin Farlow, Felix Veloso, Margaret Moline, Jane Yardley, Elimor Brand-Schieber, Francesco Bibbiani, Heng Zou, Timothy Hsu & Andrew Satlin. (2011) Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology 11:1.
Crossref
Crossref
Sohita Dhillon. (2011) Spotlight on Rivastigmine Transdermal Patch†. Drugs & Aging 28:11, pages 927-930.
Crossref
Crossref
Laxeshkumar Patel & George T. Grossberg. (2011) Combination Therapy for Alzheimerʼs Disease. Drugs & Aging 28:7, pages 539-546.
Crossref
Crossref
Sohita Dhillon. (2011) Rivastigmine Transdermal Patch. Drugs 71:9, pages 1209-1231.
Crossref
Crossref
R. Blesa González, M. Boada Rovira, C. Martínez Parra, D. Gil-Saladié, C.A. Almagro & A.L. Gobartt Vázquez. (2011) Evaluación de la conveniencia del cambio de vía de administración de rivastigmina en pacientes con enfermedad de Alzheimer. Neurología 26:5, pages 262-271.
Crossref
Crossref
Rüdiger Hardeland. (2011) Cognitive Enhancers in Moderate to Severe Alzheimer's Disease. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6344.
Crossref
Crossref
R. Blesa González, M. Boada Rovira, C. Martínez Parra, D. Gil-Saladié, C.A. Almagro & A.L. Gobartt Vázquez. (2011) Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Neurología (English Edition) 26:5, pages 262-271.
Crossref
Crossref
. (2010) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 25:8.
Crossref
Crossref